Compare FSTR & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSTR | KMDA |
|---|---|---|
| Founded | 1902 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 442.3M | 460.3M |
| IPO Year | 1995 | 2013 |
| Metric | FSTR | KMDA |
|---|---|---|
| Price | $35.01 | $7.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 40.3K | ★ 108.6K |
| Earning Date | 11-02-2026 | 11-09-2026 |
| Dividend Yield | N/A | ★ 5.20% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $540,009,000.00 | N/A |
| Revenue This Year | $4.14 | $9.50 |
| Revenue Next Year | $2.54 | $12.63 |
| P/E Ratio | $79.39 | ★ $24.59 |
| Revenue Growth | ★ 1.74 | N/A |
| 52 Week Low | $24.30 | $6.55 |
| 52 Week High | $45.81 | $9.35 |
| Indicator | FSTR | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 32.00 | 41.34 |
| Support Level | $27.00 | $6.94 |
| Resistance Level | $38.92 | $8.58 |
| Average True Range (ATR) | 0.96 | 0.20 |
| MACD | -0.17 | -0.11 |
| Stochastic Oscillator | 12.53 | 13.06 |
L.B. Foster Co is a technology solutions provider of products and services for the rail and infrastructure markets. The company has two reporting segments: Rail, Technologies, and Services (Rail); and Infrastructure Solutions (Infrastructure). Maximum revenue is generated from the Rail segment, which is comprised of several manufacturing and distribution businesses that provide products and services for freight and passenger railroads and industrial companies throughout the world. The Infrastructure segment offers engineered precast concrete solutions, as well as fabricated bridge, protective pipe coating, and pipe threading offerings across North America. Geographically, the company generates maximum revenue from the United States, followed by Canada, the UK, and other markets.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.